Trading Ideas

Looking to trade with more confidence? Giles Coghlan shares expert analysis to help you spot opportunities and navigate risks in equities, forex, and commodities.

His clear, actionable outlooks are trusted by traders worldwide and featured in Reuters, WSJ, Business Insider, FT Adviser, NBC, and more.

Stay ahead with insights that cut through the noise – from one of the industry’s most respected analysts.

Novo Nordisk Aims for the Top: CagriSema

Novo Nordisk Aims for the Top: CagriSema Poised for Breakthrough

The company hopes to differentiate itself as it faces strong competition from Eli Lilly’s Zepbound, which has already demonstrated greater weight loss, and other upcoming therapies that may offer simpler dosing options.
As Novo prepares for critical clinical trial results due in December, the pressure is mounting, particularly after a 25% drop in stock value linked to lower-than-expected prescriptions for Wegovy and investor concerns

Read MoreNovo Nordisk Aims for the Top: CagriSema Poised for Breakthrough
Boeing Seasonal

Boeing’s Seasonal Opportunity Amid Financial Struggles: Is This the Dip to Buy?

Boeing’s third-quarter report brought disappointing news, with significant losses across its commercial aircraft and defense divisions. Combined, these units reported a $6.4 billion operating loss, pushing the company to announce workforce reductions and potential delays in production.

Read MoreBoeing’s Seasonal Opportunity Amid Financial Struggles: Is This the Dip to Buy?
Rio Tinto

Rio Tinto’s Seasonal Surge Aligns with $6.7 Billion Bet on Lithium

Rio Tinto recently announced its $6.7 billion acquisition of Arcadium Lithium Plc, positioning itself firmly in the lithium market—a vital mineral for electric vehicle (EV) batteries. This move is significant, considering China's dominance in lithium production and refining, which accounts for 65% of the global refined lithium output.

Read MoreRio Tinto’s Seasonal Surge Aligns with $6.7 Billion Bet on Lithium